Quantcast
Last updated on April 19, 2014 at 7:46 EDT

Latest Immunohistochemistry Stories

2011-03-29 07:00:00

EXTON, Pa., March 29, 2011 /PRNewswire/ -- Morphotek®, Inc., a subsidiary of Eisai Inc., announced today that it has entered into a collaboration and license agreement with Biocare Medical, LLC. Under the agreement, the parties will collaborate to develop and commercialize an immunohistochemical (IHC) diagnostic kit utilizing Morphotek's proprietary monoclonal antibody to specifically detect human folate receptor alpha (FRA) with Biocare's intelliPATH(TM) Automated...

2011-03-03 07:25:13

(Ivanhoe Newswire) --  Lung cancer is considered the 6th most common cause of cancer deaths in the United States.  Overall, 10-15% of lung cancers occur in people who have never smoked a single cigarette in their life.  But thanks to an inexpensive and rapid testing method, scientists can now efficiently identify a sub-group of never-smoking lung cancer patients whose tumors express a molecule associated with increased risk of disease progression or recurrence. It's a new test...

2011-02-25 13:14:17

European Multidisciplinary Conference in Thoracic Oncology news An inexpensive and rapid testing method can effectively identify a sub-group of never-smoking lung cancer patients whose tumors express a molecule associated with increased risk of disease progression or recurrence, US researchers have found. Dr Ping Yang from the Mayo Clinic, Rochester, USA, and colleagues, reported the findings at the European Multidisciplinary Conference in Thoracic Oncology (EMCTO), 24-26 February 2011,...

2011-02-12 00:00:46

Today a digitized, or computerized, form of immunohistochemistry (IHC) is revolutionizing the clinical pathology industry, helping pathologists make diagnoses with improved accuracy, efficiency and speed are invaluable to the doctors and their patients who rely on pathology results. IHC is a test used to detect disease and determine its source and how advanced it is. IHC allows pathologists to differentiate abnormal, or diseased, cells from healthy cells and is used widely, especially in...

2011-01-20 14:41:00

ROCKVILLE, Md., Jan. 20, 2011 /PRNewswire/ -- OriGene Technologies, Inc. has recently achieved a significant milestone in its quest for developing an assay for every human protein through the release of 1,500 mouse monoclonal antibodies under the TrueMAB brand. Each TrueMAB antibody is specifically developed with full-length human proteins produced in HEK293T cells and validated for critical research and diagnostic needs requiring improved antibody sensitivity and specificity. Greater than...

2010-11-12 10:44:00

BRANFORD, Conn., Nov. 12, 2010 /PRNewswire/ -- HistoRx, Inc. (privately held), a diagnostics company, announced the launch and first commercial sale this week of clinical diagnostic assays based on AQUA® technology. Genoptix, Inc. (Nasdaq: GXDX), a specialized laboratory service provider, is launching NexCourse®(1) BCa by AQUA technology, a suite of breast cancer assays based on quantitative immunohistochemistry. NexCourse BCa by AQUA technology is:...

2010-08-09 08:00:00

BURLINGAME, Calif., Aug. 9 /PRNewswire/ -- Epitomics, Inc., the rabbit monoclonal antibody company, announces today the launch of EP Clone(TM) Rabbit Monoclonal Antibodies and their detection systems for pathology applications. These diagnostic immunohistochemistry (IHC) products are manufactured by the In Vitro Diagnostic (IVD) Division of the Company. This new line of products are developed in compliance with regulation for IHC antibodies and detection systems in the United States,...

2010-06-16 05:00:00

ALISO VIEJO, Calif., June 16 /PRNewswire-FirstCall/ -- Clarient, Inc. (Nasdaq: CLRT), a premier technology and services resource for pathologists, oncologists and the pharmaceutical industry, today announced that Neal S. Goldstein, M.D., has been named the Company's Director of Surgical Pathology. He reports directly to Chief Medical Officer Kenneth J. Bloom, M.D. Dr. Goldstein is a nationally known surgical pathologist with expertise in molecular pathology, immunohistochemistry,...

2010-05-12 16:32:00

NEW HAVEN, Conn., May 12 /PRNewswire/ -- HistoRx , Inc., announced today that the U.S. Patent and Trademark Office has granted a patent protecting the company's methods for determining a cancer patient's prognosis based on sub-cellular localization of biomarkers. U.S. Patent No. 7,709,222 is issued to Yale University and inventors David Rimm, Bob Camp, Mark Gustavson and Greg Tedeschi, and is exclusively licensed to HistoRx. Use of tissue biomarkers to characterize a patient's cancer is a...

2010-02-19 16:00:00

CARLSBAD, Calif. and NEW HAVEN, Conn., Feb. 19 /PRNewswire-FirstCall/ -- Genoptix, Inc. (Nasdaq: GXDX), a specialized laboratory service provider, and HistoRx, Inc. (privately held), a diagnostics company, today announced a multi-year licensing agreement for AQUA® technology and several diagnostic assays based on it. Genoptix has obtained exclusive commercial laboratory rights in the United States to develop and perform three solid tumor assays using HistoRx's proprietary...